Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Teclistamab/Daratumumab Doublet Is Highly Effective and Tolerable for Elderly Patients With Transplant-Ineligible NDMM

December 7th 2025

The “all-antibody–based” doublet generated high VGPR or better rates and had a favorable safety profile in the front line for this patient population.

Long-Term CARTITUDE-4 Data Point to Potential Cure Fraction With Cilta-Cel in Standard-Risk R/R Myeloma

December 6th 2025

In the CARTITUDE-4 trial, 80.5% of patients with standard-risk multiple myeloma were progression-free at 2.5 years after receiving cilta-cel.

BGB-16673 Is Safe, Highly Active Regardless of Baseline Mutations or High-Risk Features in R/R CLL/SLL

December 6th 2025

In the CaDAnCe-101 study, BGB-16673 was tolerable, effective, and showed sustained disease control in high-risk, heavily pretreated, relapsed/refractory CLL/SLL.

Adjuvant Atezolizumab Generates DFS, OS Benefit Regardless of Tumor Size, Nodal Status, and Prior NAC in ctDNA+ MIBC

December 6th 2025

Findings from an exploratory analysis of IMvigor011 support the use of serial ctDNA testing to guide atezolizumab use in MIBC.

Intravesical Cretostimogene Grenadenorepvec Is Active in BCG-Naive High-Risk NMIBC

December 6th 2025

Intravesical cretostimogene grenadenorepvec was efficacious and safe in high-risk BCG-naive non–muscle-invasive bladder cancer.

Management of Peripheral Neuropathy Does Not Compromise Survival Benefit With Frontline Enfortumab Vedotin/Pembrolizumab in Urothelial Cancer

December 5th 2025

Peripheral neuropathy was linked with improved efficacy outcomes after treatment with first-line enfortumab vedotin plus pembrolizumab in urothelial carcinoma.

Belzutifan Maintains High, Durable Responses in VHL Disease–Associated Neoplasms At 5 Years

December 5th 2025

At 48 months, the majority of patients with VHL disease–associated tumors remained in response following treatment with belzutifan.

All Eyes Are on Novel Combination Therapies and Molecular Targets in MPN at ASH 2025

December 5th 2025

Ahead of the 2025 ASH Annual Meeting, experts in myeloproliferative neoplasms share the most anticipated research being presented during the meeting.

Relief of Venous Congestion May Improve Renal Preservation Despite Worse Baseline Function in RCC With IVC Thrombosis

December 4th 2025

Data from a comparative cohort study suggest that venous congestion is a modifiable driver of renal dysfunction in patients with RCC and IVC thrombosis.

Dr Randall on the Multidisciplinary Foundation of Research Into Sarcoma Survivorship

December 4th 2025

R. Lor Randall, MD, FACS, discusses the multidisciplinary nature of research aiming to develop a predictive model of sarcoma survivorship.

Gemcitabine Intravesical System Use Is Practical and Straightforward in NMIBC

December 4th 2025

Health care providers and allied health care professionals found the gemcitabine intravesical system straightforward to use and safe in NMIBC.

Addition of Daratumumab to Lenalidomide Maintenance May Improve MRD-Negative Conversion Rates in Newly Diagnosed Myeloma

December 4th 2025

Larry Anderson, MD, PhD, FACP, discusses data from AURIGA showing that daratumumab plus lenalidomide is a favorable maintenance regimen in multiple myeloma.

Dr Jänne on the Design of the FLAURA2 Trial of Osimertinib Plus Chemotherapy in EGFR+ NSCLC

December 3rd 2025

Pasi A. Jänne, MD, PhD, discusses the design of the FLAURA2 trial in EGFR+ NSCLC.

FDA Approves Pirtobrutinib for Relapsed or Refractory CLL/SLL

December 3rd 2025

The FDA has granted traditional approval to pirtobrutinib for covalent BTK inhibitor–exposed, relapsed/refractory CLL or SLL.

TARA-002 Intravesical Therapy Generates High CR Rate in BCG-Naive NMIBC With CIS

December 3rd 2025

Interim data from ADVANCED-2 show 6- and 12-month CR rates of 69.2% and 50%, respectively, with TARA-002 in this patient population.

Silevertinib Drives CNS Responses in First-Line NSCLC With Non-Classical EGFR Mutations

December 3rd 2025

Silevertinib produced responses in NSCLC harboring non-classical EGFR mutations and will also be investigated in newly diagnosed glioblastoma.

Dr Raab on Continued Investigation of Teclistamab Plus Daratumumab-Based Induction in Myeloma

December 2nd 2025

Marc S. Raab, MD, discusses future avenues for the investigation of teclistamab plus daratumumab-based induction regimens in newly diagnosed multiple myeloma.

Dr Jakubowiak on the Efficacy of KRd Maintenance Therapy Post-ASCT in Multiple Myeloma

November 28th 2025

Andrzej Jakubowiak, MD, PhD, discusses efficacy data with maintenance KRd after ASCT in multiple myeloma.

Dr Randall on the Importance of Addressing Socioeconomic Disparities to Improve Sarcoma Survivorship

November 27th 2025

R. Lor Randall, MD, FACS, discusses the potential implications of research into how socioeconomic disparities and cancer biology impact long-term outcomes in pediatric sarcoma.

Modest Efficacy Outcomes Necessitate Broader Clinical Considerations for Later-Line Treatment Selection in Refractory CRC

November 26th 2025

Tiago Biachi, MD, PhD, reviews how data from the CORRECT, SUNLIGHT, and FRESCO trials inform later-line treatment selection in refractory mCRC.